^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LTC004
i
Other names: LTC004, LTC-004
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Leto Laboratories
Drug class:
IL-15R agonist, IL-2R agonist
Related drugs:
over1year
Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy (clinicaltrials.gov)
P2, N=10, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
New P2 trial • Combination therapy • Metastases
|
Loqtorzi (toripalimab-tpzi) • LTC004
over1year
Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma (clinicaltrials.gov)
P1/2, N=30, Not yet recruiting, Letolab
New P1/2 trial • Metastases
|
LTC004
over1year
Phase II Clinical Study of LTC004 in Patients With mCRC (clinicaltrials.gov)
P1/2, N=30, Not yet recruiting, Letolab
New P1/2 trial • Metastases
|
LTC004
over1year
Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC (clinicaltrials.gov)
P2, N=20, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
New P2 trial • Combination therapy • Metastases
|
Stivarga (regorafenib) • LTC004
almost2years
A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor (clinicaltrials.gov)
P1, N=48, Not yet recruiting, Letolab
New P1 trial • Combination therapy • Metastases
|
cyclophosphamide • fludarabine IV • LTC004
almost2years
LTC004-01: Clinical Trial for Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
P2, N=26, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
New P2 trial • Combination therapy • Metastases
|
LTC004
almost3years
Study of LTC004 in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=368, Not yet recruiting, Letolab
New P1 trial • Metastases
|
IL6 (Interleukin 6) • IL1B (Interleukin 1, beta)
|
LTC004
Share via
